

07/713 624

abc

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450  
Alexandria, VA 22313 on 21 MARCH 2006

REQUEST FOR CERTIFICATE OF  
CORRECTION UNDER 37 CFR 1.322  
Docket No. MPS 11-83B.FWC  
Patent No. 6,943,282

 #35,589  
Jeff Lloyd, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicants : Michael J. Adang and John D. Kemp  
Issued : September 13, 2005  
Patent No. : 6,943,282 *Bi*  
For : Insect Resistant Plants

**Certificate**  
**MAR 27 2006**  
**of Correction**

Mail Stop Certificate of Corrections Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION  
UNDER 37 CFR 1.322 (OFFICE MISTAKE)

Sir:

A Certificate of Correction (in duplicate) for the above-identified patent has been prepared and is attached hereto.

In the left-hand column below is the column and line number where errors occurred in the patent. In the right-hand column is the page and line number in the application where the correct information appears.

**Patent Reads:**

Column 3, lines 5 and 6:

“the heta-exotoxin”

Column 5, line 63:

“use of. Ti”

**Application Reads:**

See Prel. Amend. dated April 14, 1989 (p. 1):

-- the  $\alpha$ -exotoxin --.

Page 14, line 15:

--use of Ti”.

MAR 28 2006

Column 9, lines 54 and 55:

“Merlo (1082) *supra*”

Column 18, line 28:

“may be in Planta”

Column 28, line 58:

“ligated-with”

Column 29, line 51:

“digested with XhaI”

Column 34, line 20:

“10<sup>9</sup> bacteria”

Column 35, line 21:

“8 x 10<sup>3</sup> cells/ml.”

Column 35, line 43:

“6.3 Regenerator of Plants”

Column 43, line 66:

“10<sup>7</sup>-10<sup>8</sup> ml<sup>-1</sup>,”

Column 65, line 55:

“Ostrinia (Pyrausta) nubilais”

Column 73, line 14 (claim 1):

“insecticidal protein insects”

Column 73, line 24:

“provided insecticidal protein”

See Prel. Amend. dated April 14, 1989 (p. 1):

--Merlo, (1982) *supra* --.

Page 29, line 25:

--may be in planta--.

Page 74, line 4:

--ligated with--.

Page 76, line 18:

--digested with XhoI--.

See Prel. Amend. dated April 13, 1992 (p. 2):

--10<sup>9</sup> bacteria--.

See Prel. Amend. dated April 13, 1992 (p. 2)

--8 x 10<sup>3</sup> cells/ml.--.

See Prel. Amend. dated April 13, 1992 (p. 2)

--6.3 Regeneration of Plants--.

See Prel. Amend. dated April 13, 1992 (p. 3)

--10<sup>7</sup>-10<sup>8</sup> ml<sup>-1</sup>;--.

Page 173, line 14:

--Ostrinia (Pyrausta) nubilais--.

Examiner's Amendment to claim 15:

--insecticidal proteins to insects--.

Examiner's Amendment to claim 15:

--provided insecticidal proteins--.

Column 74, line 46, claim 21:

“nucleaic acid”

Examiner's Amendments to claim 49:

--nucleic acid--.

Column 74, line 48:

“endotoxin fragments”

Examiner's Amendments to claim 49:

--endotoxin fragment—

Column 74, line 52:

“endotoxin fragments”

Examiner's Amendments to claim 49:

--endotoxin fragment—

A true and correct copy of pages 14, 48, 74, 76, and 173 of the specification as filed, as well as copies of the Preliminary Amendments filed by applicants on April 14, 1989 and April 13, 1992 and a copy of the Examiner's Amendments that support Applicants' assertion of the errors on the part of the Patent Office accompany this Certificate of Correction.

Approval of the Certificate of Correction is respectfully requested.

Respectfully submitted,



Jeff Lloyd

Patent Attorney

Registration No. 35,589

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

JL/gld

Attachments: 1. Pages 14, 48, 74, 76, and 173 of the specification as filed  
2. Copy of the Preliminary Amendment filed by applicants on April 14, 1989  
3. Copy of the Preliminary Amendment filed by applicants on April 13, 1992  
4. Copy of the Examiner's Amendments with Notice of Allowability

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,943,282 **B1**  
 APPLICATION NO. : 07/713,624  
 ISSUE DATE : September 13, 2005  
 INVENTOR(S) : Michael J. Adang and John D. Kemp

Page 1 of 3

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3:

Lines 5-6, "the heta-exotoxin" should read --the  $\alpha$ -endotoxin--.

Column 5:

Lines 5-6, "use of. Ti" should read --use of Ti--.

Column 9:

Lines 54-55, "Merlo (1082) *supra*" should read --Merlo (1982) *supra*--.

Column 18:

Line 28, "may be in Planta" should read --may be in planta--.

Column 28:

Line 58, "ligated-with" should read --ligated with--.

Column 29:

Line 51, "digested with XhaI" should read --digested with XhoI--.

Column 34:

Line 20, "109 bacteria" should read -- $10^9$  bacteria--.

Column 35:

Line 21, "8 x 103 cells/ml" should read -- $8 \times 10^3$  cells/ml--.

## MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Saliwanchik  
 P.O. Box 142950  
 Gainesville, FL 32614-2950

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MAR 28 2006

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,943,282 **B1**  
 APPLICATION NO. : 07/713,624  
 ISSUE DATE : September 13, 2005  
 INVENTOR(S) : Michael J. Adang and John D. Kemp

Page 2 of 3

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 35:

Line 43, "6.3 Regenerator of Plants" should read --6.3 Regeneration of Plants--.

Column 43:

Line 66, "107-108 ml-l" should read -- $10^7$ - $10^8$  ml<sup>-1</sup>--.

Column 65:

Line 55, "Ostrinia (Pyrausta) nubilais" should read --Ostrinia (Pyrausta) nubialis--.

Column 73:

Line 14, "insecticidal protein insects" should read --insecticidal protein to insects--.

Column 73:

Line 24, "provided insecticidal protein" should read --provided insecticidal proteins--.

Column 74:

Line 46, "nucleaic acid" should read --nucleic acid--.

## MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Saliwanchik  
 P.O. Box 142950  
 Gainesville, FL 32614-2950

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MAR 28 2006

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

PATENT NO. : 6,943,282 **B1**  
APPLICATION NO. : 07/713,624  
ISSUE DATE : September 13, 2005  
INVENTOR(S) : Michael J. Adang and John D. Kemp

Page 3 of 3

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 74:

Line 48, "endotoxin fragments" should read --endotoxin fragment--.

Column 74:

Line 52, "endotoxin fragments" should read --endotoxin fragment--.

**MAILING ADDRESS OF SENDER:**

Saliwanchik, Lloyd & Saliwanchik  
P.O. Box 142950  
Gainesville, FL 32614-2950

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

**MAR 28 2006**

# UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,943,282 **61**  
 APPLICATION NO. : 07/713,624  
 ISSUE DATE : September 13, 2005  
 INVENTOR(S) : Michael J. Adang and John D. Kemp

Page 1 of 3

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3:

Lines 5-6, "the heta-exotoxin" should read --the  $\alpha$ -endotoxin--.

Column 5:

Lines 5-6, "use of. Ti" should read --use of Ti--.

Column 9:

Lines 54-55, "Merlo (1082) *supra*" should read --Merlo (1982) *supra*--.

Column 18:

Line 28, "may be in Planta" should read --may be in planta--.

Column 28:

Line 58, "ligated-with" should read --ligated with--.

Column 29:

Line 51, "digested with XhaI" should read --digested with XhoI--.

Column 34:

Line 20, "109 bacteria" should read -- $10^9$  bacteria--.

Column 35:

Line 21, "8 x 103 cells/ml" should read -- $8 \times 10^3$  cells/ml--.

## MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Saliwanchik  
 P.O. Box 142950  
 Gainesville, FL 32614-2950

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MAR 28 2006

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 6,943,282 **61**  
APPLICATION NO. : 07/713,624  
ISSUE DATE : September 13, 2005  
INVENTOR(S) : Michael J. Adang and John D. Kemp

Page 2 of 3

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 35:

Line 43, "6.3 Regenerator of Plants" should read -6.3 Regeneration of Plants--.

Column 43:

Line 66, "107-108 ml-l" should read -10<sup>7</sup>-10<sup>8</sup> ml<sup>-1</sup>--.

Column 65:

Line 55, "Ostrinia (Pyrausta) nubilaiis" should read "Ostrinia (Pyrausta) nubialis--.

Column 73:

Line 14, "insecticidal protein insects" should read -insecticidal protein to insects--.

Column 73:

Line 24, "provided insecticidal protein" should read -provided insecticidal proteins--.

Column 74:

Line 46, "nucleaic acid" should read -nucleic acid--.

MAILING ADDRESS OF SENDER:

Saliwanchik, Lloyd & Saliwanchik  
P.O. Box 142950  
Gainesville, FL 32614-2950

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

MAR 28 2006



UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

PATENT NO. : 6,943,282 **61**  
APPLICATION NO. : 07/713,624  
ISSUE DATE : September 13, 2005  
INVENTOR(S) : Michael J. Adang and John D. Kemp

Page 3 of 3

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 74:

Line 48, "endotoxin fragments" should read --endotoxin fragment--.

Column 74:

Line 52, "endotoxin fragments" should read --endotoxin fragment--.

MAILING ADDRESS OF SENDER:  
Saliwanchik, Lloyd & Saliwanchik  
P.O. Box 142950  
Gainesville, FL 32614-2950

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

**MAR 28 2006**



promoters in structure, and they appear to function only in the transformed plant cell. The Ti plasmid also carries genes outside the T-DNA region. These genes are involved in functions which include opine catabolism, oncogenicity, agrocin sensitivity, replication, and autotransfer to bacterial cells. The Ri plasmid is organized in a fashion analogous to the Ti plasmid. The set of genes and DNA sequences responsible for transforming the plant cell are hereinafter collectively referred to as the transformation-inducing principle (TIP). The designation TIP therefore includes both Ti and Ri plasmids. The integrated segment of a TIP is termed herein "T-DNA" (transferred DNA), whether derived from a Ti plasmid or an Ri plasmid.

Chilton, M-D. (June 1983) Sci. Amer. 248(6):50-59, has recently provided an introductory article on the use of Ti plasmids as vectors. Recent general reviews of Agrobacterium-caused disease include those by Merlo, D.J. (1982) Adv. Plant Pathol. 1:139-178; Ream, L.W. and Gordon, M.P. (1982) Science 218:854-859; and Bevan, M.W. and Chilton, M-D. (1982) Ann. Rev. Genet. 16:357-384; Kahl, G. and Schell, J. (1982) Molecular Biology of Plant Tumors, and Barton, K.A. and Chilton, M-D. (1983) Methods Enzymol. 101:527- 539.

and the various crystal proteins of B. thuringiensis. The term crystal protein should be understood to refer to both the full-length protoxin and toxin forms, to toxic proteins related to the protein which is found in the crystalline inclusion bodies of Bacillus thuringiensis, and to artificial modifications of naturally occurring crystal proteins. Related proteins might be identified by nucleic acid or protein structural or sequence homology, immunological cross-reactivity, or cross-hybridization of nucleic acids.

Plant tissue: Includes differentiated and undifferentiated tissues of plants including, but not limited to roots, shoots, pollen, seeds, tumor tissue, such as crown galls, and various forms of aggregations of plant cells in culture, such as embryos and calluses. The plant tissue may be [in planta or] in organ, tissue, or cell culture, and may be derived from plants which include, but are not limited to, those listed in Table 2.

Plant cell: As used herein includes plant cells in planta and plant cells and protoplasts in culture, and may be derived from plants which include, but are not limited to those listed in Table 2.

Production of a genetically modified plant expressing an insecticide structural gene introduced via T-DNA

residues in DNA, so that the otherwise methylated ClaI sites can be cut. After purification of that plasmid from GM33 (pKS-proI(Bam)), a partial digestion is done with ClaI and the resulting mixture [is ligated with] the ClaI/kan fragment described above. After transformation into E. coli K802, transformants are selected on tetracycline and kanamycin containing media. After plasmid isolation and restriction mapping, a clone having the desired construction is identified and the plasmid found in this  
5  
10 clone is labeled p11-83a (Fig. 3).

p11-83a has a kan gene-bearing fragment ligated into the "middle" ClaI site about 30 bp past the second polyadenylation site. The BamHI fragment of the insecticide gene, isolated from the modified vector constructed in Example 2.1, is now ligated into the BamHI site of BamHI-linearized p11-83a that has been transferred to and grown in K802 and is methylated. After transformation into K802, tetracycline and kanamycin selection, plasmid isolation, and restriction enzyme mapping, the desired construction having the insecticide structural gene inserted between the pTil5955 "1.6" promoter and polyadenylation site is identified, and the plasmid harbored therein is labeled p11-83b (Fig. 3).

ampicillin and kanamycin were restriction mapped and one having the structure shown in Fig. 3 was labeled pKS-4. pKS-4 DNA may be isolated from E. coli C600 (pKS-4) which has been deposited as NRRL B-15394.


### 5 Example 3

This example teaches another method of inserting an expressible gene for the B. thuringiensis insecticidal protein into a plant genome. The shuttle vector is similar to that used by Fink, C.L. (1982) M.S. thesis, University  
10 of Wisconsin-Madison, to put the nos gene into an octopine Ti plasmid. In the present invention, the protein coding sequences for nos are removed and replaced with an insecticidal gene before insertion into the Ti plasmid. The eventual result is an octopine-type Ti plasmid carrying  
15 an insecticide gene expressible in plant cells under control of a nopaline synthase promoter.

#### 3.1 Moving the nos gene into M13mp7

pCF44 DNA (Fink, supra) was digested [with XhoI,  
religated to itself, and transformed back into K802.  
20 Plasmid DNA isolated from ampicillin-resistant transformants was analyzed with restriction enzymes. A plasmid having a single XhoI site within its Ti plasmid-derived DNA sequences was designated pCF44A. The

- Noctua (Triphaena) pronuba  
 Nomophila noctuella (lucerne moth)  
 Nymphalis antiopa (mourning-cloak butterfly)  
 Oiketicus moyanoi
- 5 Ommatopteryx texana  
 Operophtera brumata (winter moth)  
 Opsophanes sp.  
 O. fagata  
 Orgyia (Hemerocampa) antiqua
- 10 O. leucostigma (white-marked tussock moth)  
 O. (H.) pseudotsugata (Douglas-fir tussock moth)  
 O. thyellina  
 Orthosia gothica
- [ Ostrinia (Pyrausta) nubilalis (European corn borer) ]
- 15 Paleacrita vernata (spring cankerworm)  
 Pammene juliana  
 Pandemis dumetana  
 P. pyrusana  
 Panolis flammea
- 20 Papilio cresphontes (orange dog)  
 P. demoleus  
 P. philenor  
 Paralipsa (Aphemis) gularis  
 Paralobesia viteana  
 Paramyelois transitella  
 Parnara guttata  
 Pectinophora gossypiella (pink bollworm)



## Notice of Allowability

### Application No.

07/713,624

### Examiner

Anne R. Kubelik

### Applicant(s)

ADANG ET AL.

### Art Unit

1638

-- **MAILING DATE** of this communication appears on the cover sheet with the correspondence address--  
All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to Board of Appeals decision oof 3/26/03.
2. ☒ The allowed claim(s) is/are 15-17, 22, 24-27, 29-32, 34, 40, 42-44, 46-50 and 57 renumbered 1-23, respectively.
3. ☒ The drawings filed on 20 October 1988 are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) ☐ All    b) ☐ Some\*    c) ☐ None    of the:
  1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  
**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
  6. ☐ CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
    - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
      - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date \_\_\_\_\_.
    - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.
- Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

### Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08),  
Paper No./Mail Date \_\_\_\_\_
4. ☐ Examiner's Comment Regarding Requirement for Deposit  
of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☒ Interview Summary (PTO-413),  
Paper No./Mail Date \_\_\_\_\_
7. ☒ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other \_\_\_\_\_



*Examiner's Amendment*

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Jeff Lloyd on 7 July 2004.

Claims 18-21, 23, 28, 33, 35-39, 41, 51-56 and 58-67 are cancelled without prejudice.

In claim 15, in line 1, "controlling" was replaced with --providing insecticidal proteins to-- and in line 12, "controlled" was placed with -- provided insecticidal proteins--.

2  
Claim 16 (amended). A plant cell capable of regeneration, wherein the plant cell is transformed with a nucleic acid encoding [to comprise] a *Bacillus thuringiensis* crystal endotoxin [protein insecticidal gene] under control of a promoter such that said [gene] endotoxin is [expressible] expressed in insecticidal amounts in plant tissue regenerated from said cell [in insecticidal amounts].

4  
32 Claim 22 (amended). [A] The plant cell of claim 16, wherein said [gene] endotoxin is a full-length *Bacillus thuringiensis* crystal endotoxin [protein insecticidal gene].



Art Unit: 1638

53 Claim 24 (amended). [A] The plant tissue regenerated from [a] the plant cell of claim 16,

wherein the tissue expresses said protein [containing and expressing said gene] in insecticidal amounts.

6 Claim 25 (amended). [A] The plant regenerated from [a] the plant cell of claim 16, or a [and] progeny of [such] said plant, wherein the plant or progeny expresses said protein [containing and expressing said gene] in insecticidal amounts.

7 Claim 26 (amended). A plant cell comprising a [gene] nucleic acid encoding a *Bacillus thuringiensis* endotoxin or endotoxin fragment, wherein said [gene being] nucleic acid is under the control of a promoter functional in [such] said plant cell, wherein said [gene] endotoxin or endotoxin fragment is expressed at a level rendering [such] said cell toxic to an insect.

54 Claim 27 (amended). A dicotyledonous plant cell comprising a [gene] nucleic acid encoding a *Bacillus thuringiensis* endotoxin or endotoxin fragment, wherein said [gene being] nucleic acid is under the control of a promoter functional in [such] said plant cell, wherein said [gene] endotoxin or endotoxin fragment is expressed at a level rendering [such] said cell toxic to an insect.

9 Claim 29 (amended). A plant cell comprising a [gene] nucleic acid encoding a *Bacillus thuringiensis* var. *kurstaki* endotoxin or endotoxin fragment, wherein said [gene being] nucleic acid is under the control of a promoter functional in [such] said plant cell, wherein said [gene]

Art Unit: 1638

endotoxin or endotoxin fragment is expressed at a level rendering [such] said cell toxic to an insect.

10  
Claim 30 (amended). A dicotyledonous plant cell comprising a [gene] nucleic acid encoding a *Bacillus thuringiensis* var. *kurstaki* endotoxin or endotoxin fragment, wherein said [gene being] nucleic acid is under the control of a promoter functional in [such] said plant cell, wherein said [gene] endotoxin or endotoxin fragment is expressed at a level rendering [such] said cell toxic to an insect.

11  
Claim 31 (amended). A dicotyledonous plant cell comprising a [gene] nucleic acid encoding a *Bacillus thuringiensis* var. *kurstaki* HD-1 endotoxin or endotoxin fragment, wherein said [gene being] nucleic acid is under the control of a promoter functional in [such] said plant cell, wherein said [gene] endotoxin or endotoxin fragment is expressed at a level rendering [such] said cell toxic to an insect.

12  
Claim 32 (amended). A dicotyledonous plant cell comprising a [gene] nucleic acid encoding a *Bacillus thuringiensis* var. *kurstaki* HD-73 endotoxin or endotoxin fragment, wherein said [gene being] nucleic acid is under the control of a promoter functional in [such] said plant cell, wherein said [gene] endotoxin or endotoxin fragment is expressed at a level rendering [such] said cell toxic to an insect.

Art Unit: 1638

56  
14 78 9 10  
Claim 40 (amended). The plant cell of claim [16,] 26, 27, [28,] 29, or 30 in which the [gene] endotoxin is [a] full-length [*Bacillus thuringiensis* crystal protein gene].

In claim 42, in line 2, "28," was deleted.

57 8 9 10 16 27  
Claim 43 (amended). An insect resistant plant comprising the plant cell of claim 16, 26, 27, [28,] 29, or 30 and the insect-resistant progeny of [such] said plant, wherein the progeny comprises the nucleic acid.

In claim 44, line 1, "controlling" was replaced with -- providing insecticidal proteins to--.

58 19  
Claim 47 (amended). A plant regenerated from a plant cell which is susceptible to transformation by *Agrobacterium tumefaciens*, wherein the plant cell [and] is transformed with a nucleic acid [to comprise a full length *Bacillus thuringiensis* crystal protein insecticidal gene capable of] encoding a *Bacillus thuringiensis* crystal protein of approximately 130-135 kD, and wherein the nucleic acid is under control of a promoter such that said [gene] protein is [expressible] expressed in said plant in amounts insecticidal to Lepidopteran insects.

20  
Claim 48 (amended). A plant regenerated from a plant cell which is susceptible to transformation by *Agrobacterium tumefaciens*, wherein the plant cell [and] is transformed with a nucleic acid [to comprise a *Bacillus thuringiensis* gene capable of] encoding a *Bacillus thuringiensis* endotoxin, wherein the nucleic acid is under control of a promoter, and wherein

Art Unit: 1638

58  
cont said [gene] endotoxin is [expressible] expressed in said plant [to yield endotoxin] in amounts insecticidal to [lepidopteran] Lepidopteran insects.

---

In claim 49, in line 1, "gene" was replaced with --nucleic acid--, in line 2, "gene" was replaced with --endotoxin or endotoxin fragment--, and in line 4, the first "gene" was replaced with --nucleic acid-- and the second "gene" was replaced with --endotoxin or endotoxin fragment--

In claim 50, a comma was inserted after "49".

---

59  
23  
Claim 57 (amended). A tomato plant which has been regenerated from a tomato plant cell transformed to comprise a nucleic acid [full length *Bacillus thuringiensis* crystal protein gene capable of] encoding a *Bacillus thuringiensis* crystal protein of approximately 130 kD, wherein the nucleic acid is under control of a promoter such that said [gene] protein is [expressible] expressed in said plant in amounts insecticidal to Lepidopteran insects.

---

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik, whose telephone number is (571) 272-0801. The examiner can normally be reached Monday through Friday, 8:30 am - 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached at (571) 272-0804. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of


Art Unit: 1638

the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Anne R. Kubelik, Ph.D.

July 7, 2004



**ANNE KUBELIK  
PATENT EXAMINER**



11-83B  
April 14, 1989

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: :

Adang/Kemp : Group Art Unit: 184

Serial No. 260,574 : Examiner: Tanenholtz

Filed: October 20, 1988 :

For: INSECT RESISTANT PLANTS :

PRELIMINARY AMENDMENT

COPY

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

Sir:

Please amend the specification as follows:

IN THE SPECIFICATION

At page 2, line 3, please rewrite "w-endotoxin," as --delta-endotoxin--.

At page 2, line 14, please rewrite "vivo" as --vitro--.

At page 6, line 19, please change "&" to --beta-- and before  
"-exotoxin" (second occurrence), add "gamma".

At page 7, line 22, please rewrite "over come" as  
--overcome--.

At page 8, line 4, please rewrite "cap able" as --capable--.

At page 25, line 5, please insert --(1982)-- before "supra".

At page 25, line 6, please insert --(1982)-- before "supra".

At page 25, line 14, please insert --(1976)-- before "supra".

At page 35, line 13, please insert a comma at the end of the line following "dicot".

At page 39, line 14, please rewrite "B. thuringiensis" as --B. thuringiensis--.

At page 39, line 18, please rewrite "B." as --B.--.

At page 48, line 16, please rewrite "planta" as --planta--.

At page 66, line 12, please rewrite "E. coli" as --E. coli--.

At page 66, last line, please rewrite "E. coli" as --E. coli--.

At page 104, line 19, please insert --(1982)-- before "Curr.".

At page 108, line 3, please insert --(1983-- before "supra".

At page 108, line 11, please insert --(1983)-- before "supra".

At page 110, line 2, please rewrite "chloram phenicol" as --chloramphenicol--.

At page 113, last line, please rewrite "<sup>32</sup>P-label" as --<sup>32</sup>P-label--.

At page 116, line 21, please rewrite "KH<sub>2</sub>PO<sub>4</sub>," as --KH<sub>2</sub>PO<sub>4</sub>,--.

At page 116, line 22, please rewrite "NaHPO<sub>4</sub>." as --NaHPO<sub>4</sub>.--.

At page 117, line 25, please rewrite "Na2HCO3" as --Na2HCO<sub>3</sub>--.

At page 117, line 25, please rewrite "NaHCO3" as --NaHCO<sub>3</sub>--.

At page 118, line 14, please rewrite "Casein," as --casein,--.

At page 120, line 19, please rewrite "MgCl2," as --MgCl<sub>2</sub>,--.

At page 121, line 2, please rewrite "p-Iodonitrotetrazolium" as --p-iodonitrotetrazolium--.

At page 121, line 4, please rewrite "Diaphorase" as --diaphorase--.

At page 121, line 10, please rewrite "should begin" as --began--.

At page 127, line 5, please rewrite "form" as --from--.

At page 128, line 9, please insert --(1984)-- before "supra".

At page 130, line 19, please insert --(1984)-- before "supra".

At page 131, line 3, please rewrite "THis" as --This--.

At page 131, line 10, please delete "(REF)".

At page 137, line 1, please insert --(1983)-- before "supra".

At page 137, line 20, please insert --(1986)-- before "supra".

At page 137, line 21, please delete " (REF)".



At page 145, line 3, please rewrite "250)" as --0.250)--.

At page 147, line 7, please rewrite "41:33-50)" as  
--14:33-50)--.

At page 148, line 15, please rewrite "performed," as  
--performed on--.

At page 156, line 11, please rewrite "Memdelian" as  
--Mendelian--.

At page 159, line 8, please rewrite "science" as  
--Science--.

At page 160, line 22, please rewrite "PHysiol." as  
--Physiol.--.

#### IN THE CLAIMS

Please cancel claims 1-14.

Please rewrite claim 15 as follows:

15. (Once rewritten) A method of killing insects harmful to  
plants comprising:

- (a) transforming a plant cell capable of  
regeneration to contain a Bacillus  
thuringiensis crystal protein  
insecticide structural gene and a  
plant expressible promoter whereby  
the gene is expressible in the plant  
cell under control of the promoter;

(b) regenerating said plant cell to form  
[insecticidal] plant tissue  
expressing said gene in insecticidal  
amounts; and

(c) allowing insects to feed on said  
insecticidal plant tissue whereby  
they are killed.

Please add new claims 16-25 as follows:

16. A plant cell capable of regeneration transformed to comprise a Bacillus thuringiensis crystal protein insecticidal gene under control of a promoter such that said gene is expressible in plant tissue regenerated from said cell in insecticidal amounts.
17. The plant cell of claim 16 which is a tomato plant cell.
18. The plant cell of claim 16 which is a tobacco plant cell.
19. The plant cell of claim 16 which is a maize plant cell.
20. The plant cell of claim 16 which is a cotton plant cell.
21. The plant cell of claim 16 which is a potato plant cell.
22. A plant cell of claim 16 wherein said gene is a full-length Bacillus thuringiensis crystal protein insecticidal gene.
23. A plant cell of claim 16 wherein said gene is a truncated Bacillus thuringiensis crystal protein insecticidal gene.
24. A plant tissue regenerated from a plant cell of claim 16 containing and expressing said gene in insecticidal amounts.

25. A plant or its progeny regenerated from a plant cell of claim 16 containing and expressing said gene in insecticidal amounts.

#### REMARKS

The Examiner is thanked for discussing this application with the undersigned on February 22, 1989. In accordance with that discussion, the claims hereof have been amended to cancel the vector claims, to specify the use of the Bacillus thuringiensis crystal protein insecticide gene, to specify that said gene is expressed in insecticidal amounts in plant tissue and plants, and to specify that the plant cell being transformed is one which is capable of regeneration.

Also in accordance with that discussion, the parent application, serial no. 848,733 is being expressly abandoned and the outstanding rejections therein are discussed below.

#### The Amendments

Claims 1-14 have been cancelled. Claims 16-25 have been added specifying regenerable plant cells transformed with the Bacillus thuringiensis crystal protein insecticide gene such that the plants and plant tissue regenerated therefrom are insecticidal. Claims specifying both full-length and truncated genes have been added. Support for these amendments are found in the original claims, the paragraph bridging pages 2 and 3, the paragraph bridging pages 37 and 38, the paragraph bridging pages 38 and 39, the paragraph bridging pages 58-60, and the Examples.

### The Invention

This specification represents the first demonstration of successful expression of Bacillus thuringiensis crystal protein insecticide genes in plants such that insects who naturally feed on the plants will be killed. Surprisingly, it was found that the expression of this toxic protein in plant cells did not prevent regeneration of plant tissue and whole plants expressing the gene, or kill the plant cells. Also, surprisingly, it was found that the gene could be expressed in amounts sufficient to kill the attacking insects.

Applicants, with the filing of the present continuation-in-part application disclose the actual reduction to practice of the invention with a number of important crop plant species, both monocots and dicots.

### The Rejections in the Parent Application

#### Scope

The Office Action issued in the parent application, serial no. 848,733, on January 19, 1989 rejected the claims under Section 112 stating that they were enabled only for tobacco plants transformed with a full-length Bacillus thuringiensis HD-73 gene.

This amendment narrows the claims to specify Bacillus thuringiensis genes. As was discussed with the Examiner in the interview on February 22, 1989, the present continuation-in-part application exemplifies a number of different plants and a number of different Bacillus thuringiensis insecticidal genes. A listing of some of the genes and plants exemplified is provided below. There is no reason to believe the invention would not be as operable in other plant species with other B.t. genes as it is with those plants and genes exemplified. Applicants believed, in light

of their knowledge of the mechanisms involved, at the time the grandparent application was filed, that the B.t. gene would be expressible in insecticidal quantities in any chosen plant, and this is what they claimed. Their later work showed the correctness of this position and corroborated their original claims.

This continuation-in-part application contains laboratory data showing expression of the following genes in the following plant materials:

<u>Gene</u>	<u>Plant</u>	<u>Pages</u>
Full-length HD-73	Tobacco	36,115,122
Partial HD-73	Tobacco	75,81,88
Full-length HD-73	Tomato	36,144,147
Full-length HD-73	Cotton	38,160
Full-length HD-73	Potato	159
BTt (partial)	Maize tissue	140

Also, the cited art as well as applicants' later work and the additional art discussed in the attached Declaration of Inventor Michael J. Adang shows the usefulness of B.t. genes from additional strains, thus corroborating applicants' broad enabling statements.

The Examiner cited Barton et al. and Vaeck et al. in support of his contention that it was not predictable that any B.t. gene could be used in any plant. Barton et al. reported that tobacco callus regenerated under kanamycin selection after transformation with the full-length HD-1 B.t. gene under control of a strong promoter died. Vaeck et al. reported in the text that tobacco tissue transformed with the full-length Bt2 gene from strain berliner 1715 under control of a weak promoter did not show insect-killing activity greater than the control NPTII-expressing construct; however, in Table 2, they do show insect-killing activity for this full-length Bt2 construction.

The rejection using Barton et al. and Vaeck et al. is legally improper since a reference published after an applicant's filing date may not be used to show lack of enablement. In re Hogan, 194 U.S.P.Q. 527 (C.C.P.A. 1977). Barton et al. and Vaeck et al. were both published in 1987. The application to which the rejection was applied was filed in 1986 and claimed priority to the original application filed in 1983. The present application claims priority of both earlier applications.

During the interview on February 22, 1989, the Examiner requested an explanation of the fact that applicants were able to obtain expression of a full-length B.t. gene in insecticidal amounts in tobacco without killing the tobacco tissue while other workers reported either tissue toxicity or no insect toxicity with full-length genes. Since the citation of the later-published references is improper, such an explanation should not be legally necessary, however, applicants wish to satisfy the Examiner's scientific doubts and point out the operability of their invention using the B.t. genes described in Barton et al. and Vaeck et al. and have therefore provided such an explanation in the enclosed Declaration of inventor Michael J. Adang.

Applicants submit that the plant toxicity results reported by Barton et al. and the low kill rate reported by Vaeck et al. were likely caused by failure to optimize parameters for the method of this invention. Such optimizations are well within the ordinary skill in the art once the information in applicants' disclosure is known.

To summarize the Declaration, as disclosed in applicants' specification, the full-length HD-73 gene under control of a fairly weak promoter (the T-DNA ORF 24 promoter) was expressed in low levels (up to 2 ng/mg) in tobacco. These levels were sufficient to kill insects in bioassays, but considerably lower than the

levels reported by Barton et al. (12 ng/mg) when the full-length HD-1 gene was expressed under control of a strong (CaMV 35S promoter) in tobacco. The Vaeck et al. promoter was the same weak promoter used by applicants. The Vaeck et al. results are comparable or very slightly lower than those achieved by applicants. The lower insect-killing activity achieved by both Vaeck et al. and applicants using the full-length gene with a weak promoter is still useful, all as set forth in the attached Inventor's Declaration.

Applicants cannot explain the inconsistencies in the literature which the Examiner has cited. Any attempt at an explanation is merely speculative. It sometimes happens in the early stages of research in complex systems that workers using different constructs, different test organisms, different media, etc. may fail to achieve optimum results. Such inconsistencies are to be expected. The Cohen-Boyer process itself cannot operate properly without the optimal functioning of all its components: proper reaction conditions for each restriction enzyme, each ligase, and proper host cells that lack incompatible plasmids, etc. etc. All such details are matters of optimization that those of ordinary skill in the art can perform without undue experimentation. In any event, Applicants know of no undisclosed operating parameters that could render the invention as taught and claimed inoperative, other than those well-known in the art (plants must be alive, enzymes must be active, etc.).

The higher levels of toxin expressed by Barton et al. using the strong promoter may explain the apparent toxicity to the plant. The low levels of toxin expressed by Vaeck et al. using the weaker promoter may explain the low toxicity to insects. Adjustment of expression levels so as to prevent plant toxicity while retaining insect toxicity would be a matter of ordinary skill in the art, especially in light of the teachings and data presented by

applicants herein showing that this optimization can be achieved using a full-length construct.

In general, applicants achieved better results when using the partial genes than when using the full-length genes, and better results in tomato than tobacco. See, e.g., Fischhoff, et al. (1987) *Biotechnology* 5:807-813 and applicants' later data provided in the Adang Declaration. For example, the full-length HD-1 gene found to be toxic by Barton et al. to tobacco when expressed under the CaMV 35S promoter was found by applicants not to be toxic to tomato. It is not to be expected that all constructs would provide identical levels of expression. However, applicants have shown that in general, any B.t. gene can be expressed in insecticidal amounts in any plant provided system parameters are optimized according to principles known in the art, e.g., selection of appropriate promoters, enhancers and the like.

In any event, all of applicants' claims as amended require that the transformed cell be "capable of regeneration." A cell in which B.t. is expressed at levels high enough to kill the cell is, by definition, not capable of regeneration and, therefore, not within the scope of the claims.

Even in the event there might be some plants or some genes in which no insecticidal activity could be obtained by optimization (which has never been reported), or if obtaining expression in a particular instance involved a higher level of skill than that of the ordinary skilled worker, this would in no way invalidate applicants' claims. It is well settled that it is not the function of claims to exclude all inoperative species. In re Dinh-Nguyen et al., 181 U.S.P.Q. 46 (C.C.P.A. 1974), Ex parte Janin 209 U.S.P.Q. 761 (Pat. Off. Bd. Appl. 1979).

The purpose of a specification is not to teach how to make all possible combinations and permutations of an invention. It is to



teach the best mode and to provide clear guidelines to infringers as to whether they are infringing or not. This applicants have done. Applicants were the first to show that B.t. genes could be expressed in plants so as to make them lethal to insects attacking them, and they are entitled to patent protection commensurate in scope with this important discovery.

#### Obviousness

The Office Action issued in the parent application rejected the claims based on a combination of references which teach the expression of antibiotic resistance genes in plant cells. As applicants have previously argued, expression of such genes in plant cells does not make it obvious that an insecticidal toxin such as B.t. could be expressed in plant tissue so as to render such tissue insecticidal. Insecticides are poisons and might be expected to be lethal to the cells producing them. In fact, as the Examiner points out, Barton et al. disclose that the full-length HD-1 gene expressed under control of a strong promoter is toxic to tobacco cells.

At least four important factors were unknown and could not have been predicted prior to applicants' invention: (a) that B.t. could be expressed in plant cells in amounts that were not lethal to the plant cells; (b) that plant tissues and plants could be regenerated from cells transformed with toxic B.t. proteins; (c) that B.t. could be expressed in plant cells in amounts that would kill insects; and (d) that plants expressing the B.t. gene would actually be toxic to insects without further treatment, e.g., by arranging to have the toxin excreted from the plant cells. The unpredictability of all these factors means that the requisite reasonable predictability of success required for an obviousness rejection is not present in this instance and the claims should be found to be non-obvious over the prior art. In re O'Farrell, 7 U.S.P.Q. 2d 1673 (C.A.F.C. 1988) cited by the Examiner involved

only one predictable factor, not the several unpredictable factors of the present case.

The Examiner supports his position that success is predictable based on the fact that B.t. is used on crops. Applicants point out, however, that when B.t. is applied topically to plants, it is not placed inside the cell where it might be toxic as in the present invention, and one would not know whether insecticidal amounts of toxin could be present in a transformed cell without killing the cell or whether other intracellular components might bind to the toxin and inactivate it. Applicants showed that indeed plants could be transformed to make them insecticidal.

The Examiner also supports his position that success is predictable by referring to "the primary references' use of antibiotic genes which encode compounds known to be lethal to microbial life forms." However, the primary references disclose antibiotic resistance genes, not antibiotic genes. In many instances, bacteria which produce antibiotic genes also produce corresponding resistance genes without which the bacteria would be killed by the antibiotic (e.g., the Streptomyces bacteria). No B.t. resistance gene had been identified, and it might have been expected that such a gene would have been required along with the B.t. toxin gene in order to avoid toxicity to the host organism. However, applicants showed that such was not the case and that it was possible to achieve viable regenerated plants containing a B.t. toxin gene without a B.t. resistance gene.

#### Conclusion

In view of the foregoing arguments and amendments, it is submitted the application is in condition for allowance, and passage to issuance is respectfully requested.

It is believed that the present amendment does not require the payment of any additional fees under 37 C.F.R. §1.16-1.17. If this is incorrect however, please charge any fees required under the foregoing rules to deposit account no. 071969.

Should the Examiner wish to maintain any of the rejections discussed above, a telephone interview is respectfully requested and the Examiner is invited to telephone the undersigned to arrange a mutually convenient time.

Respectfully submitted,



Ellen P. Winner  
Reg. No. 28,547

Greenlee and Associates  
5370 Manhattan Circle  
Suite 201  
Boulder, CO 80303  
(303) 499-8080

Attorney Docket No. 11-83B

leb: 4/14/89



April 13, 1992

FWC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  
MICHAEL J. ADANG and  
JOHN D. KEMP

RECEIVED BY  
PATENT LAW  
APR 16 1992

Serial No.: 07/713,624

: Group Art Unit: 1804

Filed: June 10, 1991

: Examiner: Dr. Che Chereskin

For: INSECT RESISTANT PLANTS

:

Attorney Docket No. 7285-012

1155 Avenue of the Americas  
: New York, New York 10036

PRELIMINARY AMENDMENT UNDER 37 C.F.R. §1.115

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

S I R:

This pending application was filed June 10, 1991 as a File Wrapper Continuation Application of its immediate parent application Serial No. 07/260,574 filed October 20, 1988, which was a CIP application of Serial No. 848,733, filed April 4, 1986, which was a CIP of the first filed application in this chain, Serial No. 535,354 filed September 26, 1983. The Applicants submit herewith this preliminary amendment, responsive to the December 11, 1990 Office Action filed in the '574 parent application. This Amendment is accompanied by 1) the Declaration of Dr. Guy A. Cardineau Under 37 C.F.R. §1.132 with attached Exhibits 1-12; 2) three references indicated as Exhibits A-C to the Preliminary Amendment; 3) the corresponding PTO Form 1449; 4) Appendix A with page correlations between the first and third specifications; and 5) a fee sheet for the amendment provided in duplicate.

Prior to examination of the above-captioned pending application, Applicants respectfully request that the following amendments, remarks and accompanying declaratory evidence be entered and made of record in the application.

Prior to examination of the above-captioned pending application, Applicants respectfully request that the following amendments, remarks and accompanying declaratory evidence be entered and made of record in the application.

On page 57, line 12, please change "Transferable" to  
--transferable --.

-- GATCC---3'  
C---5'--.

-- a) 5'AGGGTGCATTTGA\*AGCTTGAATAAGTAAGAACTAAAATGC3'  
...AGGGTGCATTTGT GTACTGAATAAGTATGAAGCTAAAATGC...

On page 92, line 3, please delete "103" and insert therefor --  $10^3$  --.

-- 6.3 Regeneration of Plants --.

On page 100, line 16, between "production" and "single-stranded", please add -- of --.

On page 100, line 17, between "vector" and "ssDNA", please delete "." and add --, the --.

On page 108, line 12, please delete "promote" and insert therefor -- promoter --.

On page 111, line 4, please delete "pBR322Bam-DNA" and insert therefor -- pBR322Bam-DNA --.

On page 111, line 9, please delete "BAM-'s "and insert therefor -- BAM-'s --.

On page 115, last line, please delete "107-108" and insert therefor --  $10^7$ - $10^8$  --.

On page 116, line 1, please delete "ml-1" and insert therefor -- ml<sup>-1</sup> --.

On page 116, between line 10 and line 11, please insert the paragraph heading as follows:

-- 12.8 Expression in Plant Tissue: Immunoassay --.

On page 123, line 3, between "leaves," and "but", please insert -- (1 for smallest and 10 for largest) --.

On page 124, line 5, between "plant" and "It", please insert -- . -- to end the sentence.

On page 125, line 7, please delete "if" and insert therefor -- of --.

On page 138, line 13, please delete "expect" and insert therefor -- except --.

On page 139, line 19, please delete "13.8" and insert therefor -- 13.9 --.

On page 156, line 11, please delete "Memdelian" and insert therefor -- Mendelian --.

On page 161, line 7, please delete "122" and insert therefor -- 12 --.

On page 185, line 12, please delete "dNRRL B-15486" and insert therefor -- NRRL B-15486 --.

On page 141, at the untitled table, please make the following changes:

delete "μg p461:162-191 DNA" and insert therefor

-- μg p461:162-191 DNA;<sup>1</sup> --

and add footnote 1 as follows:

-- <sup>1</sup> See Section 13-6, page 132 for a description of the plasmid construction. --.

IN THE CLAIMS

Please amend Claim 15 as follows:

15. (Twice amended) A method of [killing] controlling insects harmful to plants comprising:

- (a) transforming a plant cell capable of regeneration to contain a *Bacillus thuringiensis* crystal protein insecticide structural gene and a plant expressible promoter whereby the gene is expressible in the plant cell under control of the promoter;
- (b) regenerating said plant cell to form plant tissue expressing said gene in insecticidal amounts; and
- (c) allowing insects to feed on said insecticidal plant tissue whereby they are [killed] controlled.

Please add new Claims 26-46 as follows:

-- 26. A transformed plant cell comprising a gene encoding a *Bacillus thuringiensis* crystal protein or protein fragment, which gene is under the control of a promoter functional in such plant cell, to which plant cell insect resistance is conferred by the expression of the gene encoding the crystal protein or protein fragment in an amount which is toxic to an insect.

27. A transformed dicotyledonous plant cell comprising a gene encoding a *Bacillus thuringiensis* crystal protein or protein fragment, which gene is under the control of a promoter functional in such plant cell, to which plant cell insect resistance is conferred by the expression of the gene encoding the crystal protein or protein fragment in an amount which is toxic to an insect.

28. A transformed monocotyledonous plant cell comprising a gene encoding a *Bacillus thuringiensis* crystal protein or protein fragment, which gene is under the control of a promoter functional in such plant cell, to which plant cell insect resistance is conferred by the expression of the gene encoding the crystal protein or protein fragment in an amount which is toxic to an insect.

29. A transformed plant cell comprising a gene encoding a *Bacillus thuringiensis* var. *kurstaki* crystal protein or protein fragment, which gene is under the control of a promoter functional in such plant cell, to which plant cell insect resistance is conferred by the expression of the gene encoding the crystal protein or protein fragment in an amount which is toxic to an insect.

30. A transformed dicotyledonous plant cell comprising a gene encoding a *Bacillus thuringiensis* var. *kurstaki* crystal protein or protein fragment, which gene is under the control of a promoter functional in such plant cell, to which plant cell insect resistance is conferred by the expression of the gene encoding the crystal protein or protein fragment in an amount which is toxic to an insect.

31. A transformed dicotyledonous plant cell comprising a gene encoding a *Bacillus thuringiensis* var. *kurstaki* HD-1 crystal protein or protein fragment, which gene is under the control of a promoter functional in such plant cell, to which plant cell



insect resistance is conferred by the expression of the gene encoding the crystal protein or protein fragment in an amount which is toxic to an insect.

32. A transformed dicotyledonous plant cell comprising a gene encoding a *Bacillus thuringiensis* var. *kurstaki* HD-73 crystal protein or protein fragment, which gene is under the control of a promoter functional in such plant cell, to which plant cell insect resistance is conferred by the expression of the gene encoding the crystal protein or protein fragment in an amount which is toxic to an insect.

33. The plant cell of claim 27 or 29 which is a tobacco plant cell.

34. The plant cell of claim 27 or 29 which is a tomato plant cell.

35. The plant cell of claim 27 or 29 which is a cotton plant cell.

36. The plant cell of claim 27 or 29 which is a potato plant cell.

37. The plant cell of claim 16, 27 or 29 which is a carrot plant cell.

38. The plant cell of claim 16, 27 or 29 which is a sunflower plant cell.

39. The plant cell of claim 16 or 28 which is a maize plant cell.

40. The plant cell of claim 16, 26, 27, 28, 29 or 30 in which the gene is a full-length *Bacillus thuringiensis* crystal protein gene.

41. The plant cell of claim 16, 26, 27, 28, 29 or 30 in which the gene is a truncated *Bacillus thuringiensis* crystal protein gene.

42. Insect-resistant plant tissue comprising the plant cell of claim 16, 26, 27, 28, 29 or 30.

43. An insect-resistant plant comprising the plant cell of claim 16, 26, 27, 28, 29 or 30, and the insect-resistant progeny of such plant.

44. A method for controlling insects harmful to plants comprising allowing insects to ingest the plant tissue of claim 42.

45. A method for controlling insects harmful to plants comprising allowing insects to ingest the plant of claim 43.

46. The plant cell of claim 16 or 26 to which cell resistance to an insect from the group Lepidoptera, Coleoptera, Diptera, Hymenoptera, Mallophaga, and Trichoptera is conferred.

#### REMARKS

Attorneys for Applicants take this opportunity to thank Examiner Chereskin for allowing them the opportunity to speak with her and for the courtesy extended to them in the interview of October 31, 1991. Applicants in this amendment provide arguments and evidentiary support affirming the discovery by Applicants of a pioneering invention which derives the benefit of priority from the earliest filed application and is entitled to claims of broad scope.

Applicants have amended claim 15 to particularly point out and distinctly claim the subject matter of the invention. Insect resistance and/or the ability to control insects is particularly described in the specification at page 35, line 5; page 37, line 2; page 38, lines 14-17; page 39, line 6 through page 40, line 7; page 47, lines 5 through 20; page 61, lines 8-21; and in §12.9 at pages 121-125. Applicants note that the definition of insecticidal protein provided in the pending specification at page 47, i.e. "a protein or peptide that is directly or indirectly toxic or growth inhibitory under any circumstances to any insect" is in accordance with the dictionary

definition. Webster's Third New International Dictionary (copyright 1981) defines insecticidal as "destroying or controlling insects."

Applicants have added new Claims 26 to 46 which correspond to particular embodiments of the subject matter of the application that is unquestionably patentable as discussed with the Examiner during the interview. Newly added Claims 26 to 46 are, in their broadest scope, directed to a transgenic plant cell, tissue or plant to which the gene encoding a Bt insecticidal protein or active fragment under control of a functional promoter has been added and is expressed in amounts which are toxic to an insect.

Additional independent claims and claims dependent on the newly added and pending claims particularly point out and distinctly claim specific subject matter which Applicants regard as their invention which includes dicotyledonous and monocotyledonous plant cells, cells containing kurstaki crystal protein or fragments thereof, the kurstaki HD-1 or HD-73 embodiment thereof, specific types of plant cells, a method for controlling specific types of insects, full-length and truncated crystal protein embodiments, regenerated plant tissue, regenerated plants and methods for controlling insects using such plant cells, tissues or plants expressing an insecticidal protein. The newly added claims are supported in the pending specification at pages 20 to 196 and in the three figures. Particular support for different aspects of the claimed invention are discussed herein in detail at sections 1-7 of the "Claim To Priority" found below in §I below.

**I. THE INVENTION AND ITS CLAIMS TO PRIORITY UNDER 35 U.S.C. §120**

**The Invention**

By September 26, 1983, well in advance of any other scientists in the world, inventors Michael Adang and John Kemp had conceived and reduced to practice genetically modified plant cells and plants expressing an insecticidal Bacillus thuringiensis (hereinafter "Bt") protein or protein fragment under the control of a plant expressible promoter such that insect pest resistance was conferred to the plant cell, tissue or plant (as taught in specification Serial No. 535,354 beginning at page 20).<sup>11</sup> In various embodiments and examples, the inventors described how to stably insert a gene coding for an insecticidal protein from Bt bacteria into the genome of a plant cell and described how to test its expression in plant tissues of a normal plant (page 54). Following ingestion of the genetically modified plant cells by insects, the insects are poisoned and thereby controlled (page 56, and see Serial No. 07/713,624 page 96 and pages 121-125 for more detailed results).

This novel feat, by no means minor, required numerous scientific steps which are detailed in the specification and

<sup>11</sup> Unless noted to the contrary, all pagination refers to the first filed specification, Serial No. 535,354. Applicants recognize the difficulty encountered by the Examiner in view of the different type faces and resulting change in page numbers between the first filed application Serial No. 535,354, filed September 26, 1983; the second, CIP application Serial No. 848,733 filed April 4, 1986; the third application, which was also a CIP, Serial No. 07/260,574, filed October 20, 1988, the page numbering of which is identical to the pending FWC application Serial No. 07/713,624, filed June 10, 1991.

A table is attached hereto as Appendix A which correlates the page numbers of the first specification with the pending specification since a different type face was used to produce the CIP applications. This type face alteration resulted in a change of pagination but essentially no change was made in the disclosure other than the amplification of the invention by the disclosure of additional working examples which were appended to the end of the first specification.

include 1) the genetic manipulations needed to produce appropriate vectors and constructs that allow stable recombination into plant cells and expression of the Bt insecticidal gene from a promoter in the plant cells; 2) methods for transformation; 3) regeneration of the plant cells to produce plants; and 4) the tests needed to characterize the plants so produced.

The invention of Drs. Adang and Kemp, reduced to practice in the disclosure of Serial No. 535,354 and further exemplified in different embodiments in Serial Nos. 848,733 and 07/260,574, is broadly operable as indicated by the color photographs attached as exhibits to the Declaration of Dr. Guy A. Cardineau, filed concurrently with this amendment. The color photographs portray numerous healthy, stably transformed insecticidal plants which are startling when compared with the ravaged and decimated non-insecticidal control plants.

Worth far more than any attempt at description by words in this amendment, the visual evidence of the sickly insect survivors present on healthy insecticidal plants as compared to healthy insects found on the chewed up skeletons of non-insecticidal plants in the photograph of Exhibit 2, attests to the value, utility and significance of the invention. The foresight of the inventors, Dr. Michael Adang and Dr. John Kemp, in conceiving and then reducing this invention to practice well before any other scientists in the world, can not be minimized. One need only look to the date of publication of the art cited by the Examiner in the outstanding Office Action of 07/260,575 to recognize that the inventors reduced their invention to practice years before published reports of similar results by others. This pioneering invention thus performed a function not found in any earlier invention in a scientific area devoid of prior art.

### The Claim To Priority

Applicants respectfully bring to the Examiner's attention the requirements needed to establish priority under 35 U.S.C. §120. These requirements are 1) that the applications have co-pendency; 2) have continuity of inventorship; 3) have specific reference to each prior application; and 4) have a disclosure in compliance with the first paragraph of 35 U.S.C. §112.

Applicants claim priority under 35 U.S.C. §120 to the first application filed September 26, 1983. The applications fulfill the co-pendency requirement because each application was filed during pendency of its parent. The applications fulfill the inventorship requirement because Drs. Adang and Kemp are the named inventors of all four applications in the chain. The applications contain or were amended to contain a reference to the earlier filed applications. Compliance with the first paragraph of 35 U.S.C. §112 is discussed below where support for the claims is identified in the specification as first filed. Additional reasons for compliance with 35 U.S.C. §112 are provided in the responses to the specific rejections of the claims.

The claims are directed to a genetically altered plant cell, tissue or plant expressing a structural gene encoding a insecticidal Bt crystal protein. The claimed cell is capable of regeneration into plant tissue and plants. The relevant disclosures related to aspects of the pending claims are noted below for specific pages of the first filed specification.

- 1) Plant cells, plant tissue and plants  
which can be made insect-resistant

The types of plants included in the disclosure of the first application as encompassed by the invention are any plant species (see, e.g. p. 22) including dicots (p. 20; p. 21, cotton or tobacco; p. 22, gymnosperms, sunflower, tobacco, soybeans,

legumes, cotton, most vegetables; p. 76, a variety of plants protectable by the invention) and monocots (p. 33; p. 76, plants protectable against insects include alfalfa, field corn, forage crops, hay, pasture plants, stored corn, stored grains, sweet corn and turf). The definition of plant cells and plant tissue on p. 27-28 includes plant cells in plants, in culture and those derived from plants. The CIP applications further exemplify different plant cells, tissues and plants used in the invention. The cells of the invention include those within plants, those derived from plants and differentiated or undifferentiated cells. The plant tissues of the invention include various plant tissues such as those from normal tissues like leaves and roots, as well as those of galls, embryos, calluses, or tissues grown in cell culture. Plants of the invention include those comprising a plant cell having a gene encoding a crystal protein or protein fragment under the control of a promoter functional in such plant cells, in which the plants are produced by any method of propagation.

2) Genetic alterations

The invention is directed to plant cells and plants, the genetic make-up of which has been altered by the insertion of heterologous DNA through any means known in the art (p. 21). The constructs are introduced into plant cells by both physical and biological methods. The examples of the disclosures describe in great detail the various constructs having different promoters and different insecticidal genes. The genetic methods used to stably recombine the promoter and Bt insecticidal gene of the constructs into plant cells are also described in detail in the examples. Large portions of the first specification are devoted to descriptions of the Agrobacterium method which was the preferred embodiment at the time of the filing of the first application, although alternative embodiments are described in

the first application. The alternative means described are directed to both physical and biological methods and include different methods of transformation (p. 8-10), DNA uptake (p. 10), the use of viral genome vectors, minichromosomes, transposons, and the use of homologous or nonhomologous recombination (p. 33). Alternate forms of delivery include the direct uptake of nucleic acid, liposome fusion, microinjection, and encapsidation (p. 33).

3) A Bt insecticidal structural gene

The application notes on p. 2 and 3 that crystal protein genes can be found on plasmids and on chromosomes of Bt, indicating where one of skill in the art could obtain relevant DNA samples. The specifications describe the use of a truncated, full-length, dicistronic or fusion construct of different Bt insecticidal structural genes. What is meant by a Bt insecticidal gene is defined on page 26 and 27. The invention recognizes that different proteins and varieties of Bt can be used (see p. 27 for related proteins) in addition to the sequenced Bt gene of *kurstaki* HD-73 found in Figure 1 and Example 1. A large number of useful varieties of Bt are found in Table 3 (at p. 77).

Information related to insecticidal proteins is provided in the background section of the specification and describes the methods known in the art for isolating, identifying and sequencing insecticidal proteins if a Bt insecticidal protein is desired that differs from those provided by example. The methods known in the art include directed or random cloning with a test of cloned fragments accomplished by feeding the bacteria containing the cloned fragment to insects with a subsequent bioassay to detect survival and/or weakening of the insect. Several Bt insecticidal genes had been cloned and identified prior to the filing of the first application (see p. 2-4 of the



specification). Additional examples provided in the CIP applications illustrate the use of Bt tenebrionis and the 5.3 class gene of HD-1.

4) A plant expressible promoter

The specification particularly describes and teaches expression in plant cells of an insecticidal structural gene under the control of a plant expressible promoter (p. 2 and defined at p. 24-25 and p. 29-30). The promoters exemplified specifically in the disclosure include the promoters of T-DNA (the 1.6, ocs, nos, tms, tml, tmr promoters at p. 25; the 35S and 19S transcript promoters of cauliflower mosaic virus at p. 26; the phaseolin promoter, p. 31 and p. 48-50; the 1.6 promoter, p. 40; and the nos promoter, p. 44-45). Other promoters described as additional examples in the CIP applications include the ORF 24 promoter.

5) Expression

Expression, an art recognized term, is defined in the specification at pp. 25, 28-30 and at other locations throughout the specification. Expression in *E.coli* was demonstrated in the first application in Example 1 and included an analysis of the protein including its functional activity against insects allowed to ingest the transformed bacteria. Expression in plant cells, tissues or plants is particularly described in the first application on page 47, page 51, and pages 54-56.

6) Regeneration

Regeneration of plants and plant tissue is described in the specification at p. 10-11 (for *Agrobacterium* systems using Ri or Ti plasmids); p. 21 (methods well known in the art), p. 28 (regeneration into whole plants may include steps for selecting and detecting transformed plant cells and transferring the introduced gene into commercially acceptable cultivars), p. 32 (screening methods include assays for opine production,

hybridization, immunological assays, bioassays), p. 34-35 (various aspects of regeneration known in the art and subsequent transfer into commercial cultivars), p. 47 and 51 (mating the *E.coli* strain containing the construct of the invention with *A. tumefaciens*, which harbors TIP plasmids containing mutations which facilitate regeneration; homologous recombinants selected; characterization by restriction mapping; testing using wounded sunflower stems; assay by ELISA, Western blots and bioassay; infection and regeneration of tobacco cells; development of breeding stock), p. 51-52 (regeneration of carrot tumors using Ri based TIP plasmids), and p. 52-54 (regeneration of tobacco and use of assays for screening the retention of the transformed phenotype).

The CIP applications further amplify and exemplify the invention disclosed in the first application with additional constructs that have different promoter/insecticidal gene combinations for producing additional insecticidal cells, tissues and/or plants for tobacco, corn, tomato, potato and cotton. As disclosed in the declaration of Dr. Guy A. Cardineau attached hereto, actual photographs and/or data are presented of the constructs of the invention as applied to the development of insecticidal gene expression in tobacco, tomato, cotton, potato, sunflower, and maize plant cells, tissues and/or plants, including different generations of plants. Moreover, the invention results in the production of healthy, uniformly transformed non-chimeric plants possessing stable germ-line incorporation of the insecticidal gene sequence. This allows transfer of the insecticidal gene sequence to subsequent generations by normal methods of sexual reproduction, as directly tested in various plants. The levels of expressed Bt protein and the stable incorporation of the Bt gene into the plant DNA have been analyzed by the various methods taught in the specification

including ELISA, Northern, Western and Southern blotting, and nucleic acid analysis.

7) Insecticidal amounts

The presence of insecticidal amounts of Bt protein in the plant cells, tissues or plants is analyzed by bioassay (see, e.g. specification §2.4 at p. 43, §3.6 at p. 47, §4.06 at 51, and Example 8 at p. 56). Alternatively, the insecticidal protein is itself detected or the nucleic acid encoding it is detected (see Example 7 at pp. 54-56 and Example 10 at p. 57). The characteristics of known insecticidal proteins are described at p. 1-4.

In further examples found in the additional disclosures of the CIP applications and as found in the declaration of Dr. Guy A. Cardineau, it is recognized that bioassays using insect feeding are the most sensitive method of assay for detection of the Bt insecticidal protein (see, e.g. the results of specific plant feeding experiments in Example 12 and §15.6 and §15.8 of the pending application). Moreover, worm weights of surviving larvae in bioassays were significantly lower than controls, and larvae that did not die failed to grow at normal growth rates. These types of bioassays, demonstrating the utility of the methods of the invention for controlling insects, are specifically depicted in the photographic exhibits attached to the declaration of Dr. Guy A. Cardineau, filed with this amendment. Significantly, the disclosures of the applications indicate that multiple generations or plants have been tested by bioassay and other methods. A careful analysis has been accomplished over a period of years to establish the stability of the inserted Bt genes and their insecticidal activity in cells of the different generations of selected plants. Such analyses are described not only in the pending specification at pages 193, but also in the declaration of Dr. Guy A. Cardineau.

**II. THE INVENTION IS ENABLED UNDER 35 U.S.C. §112**

In the parent Serial No. 07/260,574 application, the Examiner has rejected Claims 15-25 under 35 U.S.C. §112. Because all pending claims of Application Serial No. 07/713,624, including those added in this amendment, relate to the subject matter of Claims 15-25, Attorneys for Applicants assume that all pending claims are also rejected for the same reasons provided by the Examiner for Claims 15-25.

Attorneys for Applicants will briefly summarize the relevant legal standards under 35 U.S.C. §112, especially as they apply to pioneering inventions and will then address the specific rejections.

**A. The Relevant Legal Standards**

In *In re Robins*, 166 U.S.P.Q. 552 (C.C.P.A. 1970), the Court of Customs and Patent Appeals, the predecessor court to the United States Court of Appeals of the Federal Circuit, addressed the sufficiency of the disclosure of a specification to support claims of a broad scope. The Court recognized that representative examples are not required by statute nor are they the only way a broad enabling disclosure might be met. *Id.* at 555. This opinion of Judge Rich also indicated that 35 U.S.C. §112 "does not require that a specification convince persons skilled in the art that the assertions therein are correct." *Id.* at 556.

In *re Goffe*, 191 U.S.P.Q. 429, 431 (C.C.P.A. 1976), reversed the finding of the Board of Patent Appeals and Interferences on the issue of limitation of the claims of an application to specific materials disclosed in the examples, particularly where no prior art was relied on. In finding that the Board erred, the court opined:

For all practical purposes, the board would limit appellant to claims involving the specific materials disclosed in the examples

so that a competitor seeking to avoid infringing the claims would merely have to follow the disclosure in the subsequently-issued patent to find a substitute. However, to provide effective incentives, claims must adequately protect inventors. To demand that the first to disclose shall limit his claims to what he has found will work or to materials which meet the guidelines specified for "preferred" materials in a process such as the one herein involved would not serve the constitutional purpose of promoting progress in the useful arts.

*Id.* at 431.

B. The Pending Rejections Under 35 U.S.C. §112 Should Be Withdrawn

In the parent Serial No. 07/260,574 application, the Examiner rejects Claims 15-25, and thus all pending claims, under 35 U.S.C. §112, first and second paragraphs, on the grounds that Applicants have allegedly enabled only the Bt *kurstaki* sequence shown in Figure 1.

Attorneys for Applicants respectfully disagree with the Examiner's rejections under 35 U.S.C. §112 and submit that the claimed pioneering invention of Drs. Adang and Kemp is fully enabled by the earliest filed specification, allowing one of ordinary skill to make and use the invention without undue experimentation.

The Examiner is in error in her assertion that Applicants have enabled only the Bt *kurstaki* sequence of Figure 1. The first application describes multiple types of insecticidal proteins of a number of different bacterial strains. Moreover, the specification provides detailed instructions for methods of cloning, expressing, assaying and sequencing insecticidal proteins, including relevant insect bioassays. The Examiner's attention is directed to pages 24, 26-27 and page 77 of the first application.

Once such methods are taught by the specification of the first application, it is within the skill of the ordinary artisan to use the teachings of the application to substitute any insecticidal protein sequence for the Bt *kurstaki* sequence, which was exemplified only for purposes of illustration of the other detailed teachings of the specification.

A review of the references cited in the background portion of the first specification supports the position that, as of the filing date of the first application, the specification taught what was necessary to identify, clone and sequence numerous insecticidal proteins. Therefore it would be within the abilities of one of ordinary skill in the art to produce the claimed invention using the sequences of various insecticidal proteins obtained through the teachings of the specification.

Applicants note that the Hofte reference cited by the Examiner totally fails as art of any kind against any of the applications since it was published in 1989.<sup>2/</sup> The classification and nomenclature scheme iterated in Hofte in 1989 can not be used to limit an invention that is entitled to a priority date of 1983, or even of 1986 or 1988. Moreover, it is irrelevant that the Thorne reference cited by the Examiner points out the existence of multiple types of proteins with insecticidal activity because Applicants have provided instructions to one of ordinary skill in the art for cloning, isolating and sequencing a variety of insecticidal protein genes as described above. Moreover, Applicants have exemplified their disclosure using insecticidal protein sequences from Bt *kurstaki* HD-73, available as a deposited cell line, Bt *tenebrionis*, and a 5.3 class gene derived from Bt HD-1 dipel. This large number of examples based

<sup>2/</sup> Applicants seriously question the propriety of the Examiner's citation of numerous references, published well after Applicants' filing date to bolster her §112 rejections. See *In re Hogan*, 194 U.S.P.Q. 527, 536 (C.C.P.A. 1977).

on the teachings of the first filed application should be more than sufficient to support the pending claims because they provide a variety of constructs that allow one of skill in the art to make and use the claimed invention.

Indeed, the specification of the first application makes it abundantly clear that this novel invention, not accomplished nor published by anyone else prior to the filing of the first application, encompasses the use of any insecticidal protein gene. The specification makes clear that the invention is the development of transgenic plant cells, tissues and plants containing amounts of an expressed insecticidal protein gene sufficient to affect the growth of insects susceptible to the insecticidal protein. The specification itself discloses the use of different insecticidal protein genes for different insects and provides the knowledge to those of skill in the art that healthy insecticidal cells, tissues and plants can be successfully produced.

In the parent Serial No. 07/260,574 application, the Examiner objects to the specification and rejects Claims 15-25, and thus all pending claims, under 35 U.S.C. §112, first paragraph, for failure to provide what are asserted to be proper controls, data, and table descriptions in various of the enumerated experimental insect feeding trials of the third application. Applicants respectfully submit that these criticisms impose a higher standard upon Applicants than that called for by the statute. See *In re Robins*, 166 U.S.P.Q. at page 556.

Nevertheless, in response to the Examiner's criticisms, the Examiner's attention is directed to all of the photographic exhibits attached to the Declaration of Dr. Guy A. Cardineau which supports the Applicants' disclosure of production of healthy, stably transformed insecticidal plant cells, tissues and

plants, including plants that have been produced from seed demonstrating successful germline incorporation of the insecticidal protein gene. Applicants note that normal reproductive methods can be used with plants produced according to the methods of the invention allowing the development of numerous different plant varieties.

Photographic Exhibit 2 and 3 are the visual counterparts of the specific insect trials the Examiner objects to in the Office Action. In Exhibit 3, the transgenic highly insecticidal tobacco plant leaves (designated 100) are on the left and the weakly insecticidal plant leaves (103) are on the right in the photograph. The transgenic highly insecticidal leaves of 100 are essentially untouched while all that remains of the weakly insecticidal plant leaves of 103 are larval droppings and vein stalks. Applicants disclose at p. 124 of the specification of the 260,574 application that 103 was discovered to be a non-stably transformed chimeric plant, providing an explanation that was recognized for the variable results provided in the trial description in the specification. The variability of the 103 plant however has nothing to do with the actual insecticidal nature of the healthy non-chimeric plant 100 which represents only one of the plants of the invention. The plant of clone 100 was a healthy stably transformed plant suitable for regeneration and propagation of additional plants. Moreover, providing examples of chimeric plants actually aids the person of ordinary skill in the art in making and using the claimed invention because it provides information about the number range and types of plants that need to be examined and the kind of tests needed to be done to make and use the invention.

Exhibit 8 of the declaration of Dr. Guy A. Cardineau, provides a report of a field test of transgenic insecticidal tomato plants indicating that preliminary tobacco hornworm



feeding trials were done in laboratory growth chambers to identify active plants and involved testing of 550 plants transformed with different constructs of the invention. Forty plants survived the initial testing and were used for the field trial. Although parasitization of the insects occurred in the late stages of the field trial, bioassay results of field harvested insects were consistent with the data of the other laboratory methods which showed insecticidal protein expression with toxicity of the plants in the field equivalent to that observed in the laboratory.

In summary, Applicants have used proper controls and have provided sufficient data and taught numerous methods of testing to demonstrate that the actual plant cells, tissues and plants of the invention are insecticidal. The rejection of Claims 15-25, and thus all pending claims, under 35 U.S.C. §112 first and second paragraphs have therefore been obviated. Withdrawal of the rejection of these claims under 35 U.S.C. §112, first and second paragraphs, is respectfully requested.

In the parent Serial No. 07/260,574 application, the Examiner rejects Claims 15, 16, 19 and 22-25, and thus all pending claims, directed to both dicots and monocots under 35 U.S.C. §112, first paragraph. The Examiner asserts the claims should be limited to dicots according to MPEP §706.03. Attorneys for Applicants note that the references cited by the Examiner for the proposition that success of the invention in monocots is questionable are inappropriate since the disclosures of the references are directed to the dicot species of flax (Jordan) and tobacco (Barton). This rejection is therefore improper per se because there is no evidentiary support for the Examiner's assertions that monocot transformations using foreign genes result in sick cells, tissues or plants.

In formulating this rejection, the Examiner apparently relies on a mistaken belief that working examples are required for all species of a genus described in a specification. However, working examples are not specifically required to enable an invention if the invention is disclosed in a manner allowing one of ordinary skill in that particular art to make and use the invention. Moreover, it is unnecessary to include information already known to those of skill in the art as of the filing date of the application.

The Examiner argues that the Jordan and Barton references disclose sick transformed tissue and suggests that plants containing insecticidal genes cannot be regenerated. This argument is invalid because Applicants have amply demonstrated in the disclosures of the applications and by the declaratory, photographic and written evidence of both Dr. Adang, provided previously, and Dr. Cardineau, provided with this amendment, that the invention results in healthy non-chimeric plant cells, plant tissue and plants, including those plants capable of normal sexual reproduction allowing the transfer of the insecticidal gene to other varieties of plants.

There are multiple monocot species described in the specification of the first application that the Examiner has ignored. The first application describes the invention broadly, without limitation as to the type of plant that can be developed to produce insect resistance by expression of an insecticidal gene. There is no reason that the invention does not encompass monocots, especially because the invention has been shown to include monocots as disclosed in working example 14 found at page 140-144 of the pending specification.

With regard to what was known in the art prior to the filing of the first application, the Examiner's attention is directed to the following references which are cited on PTO Form

1449 and attached as Exhibits A to C hereto: Gengenbach et al., *Proc. Natl. Acad. Sci U.S.A.* 74(11): 5113-5117 (1977); Hibberd et al., *Proc. Natl. Acad. Sci. U.S.A.* 79: 559-563 (1982); and Green et al., *Maize for Biological Research*, ed. W.F. Sheridan, p. 367-371 Plant Molecular Biology Association (1982). These references disclose monocot regeneration and gene expression and predate the original filing date of September 26, 1983. These references demonstrate the level of ordinary skill in the art at that time and show that corn plant cells and tissues are capable of regeneration into plants following transformation and stable integration of a foreign gene.

Applicants note that the Vasil reference cited by the Examiner discloses that monocot regeneration was well known in the art for various monocots well prior to the filing date of the first application, especially following the recognition that the auxin 2,4-D in nutrient medium was sufficient for induction of callus. Vasil notes plant regeneration in Gramineae in 1977 and regeneration of rice, wheat, maize and sugarcane by 1980. Vasil continues with its description of what was known in the art related to somatic embryogenesis and identification and maintenance of embryonic calli as of 1981. At page 399, Vasil states that "[S]ince [1981] efficient and long-term regeneration has been achieved in all of the important species of grasses . . . ". Attorneys for Applicants note that grasses, Gramineae, rice, wheat, maize and sugarcane are monocots. Vasil's statements regarding monocot regeneration are really directed to the efficiency of the process and not to its predictability. Vasil therefore attests to the existence of stable transformation and regeneration in monocots and supports Applicant's position that the application provides an enabling disclosure supporting the pending claims to monocot species.

transformed plants that can be used for normal sexual propagation of the insecticidal gene and the development of different plant varieties. Applicants have provided laboratory data as well as field trial data and results for different plants produced according to the methods and teachings of the invention.

Applicants have produced a pioneering invention and disclosed it in the first application well in advance of any publication by another anywhere in the world. Applicants are therefore entitled to claims of broad scope. Applicants therefore respectfully request that this rejection of Claims 15-25 and all pending claims under 35 U.S.C. §112 first paragraph be withdrawn.

**III. THE INVENTION IS NOT ANTICIPATED UNDER 35 U.S.C. §102**

**A. 35 U.S.C. §102: The Relevant Legal Standards**

Anticipation is a narrow and technical attack on patentability. The standards to establish anticipation are strict. Not only must all material elements of the claimed invention must be disclosed within a single reference, the reference must comply with the novelty requirements of 35 U.S.C. §102 before an applicant loses his right to a patent. *In re Marshall*, 198 U.S.P.Q. 344, 346 (C.C.P.A. 1978). *Accord, Scripps Clinic & Research Foundation v. Genentech*, 18 U.S.P.Q.2d 1001, (Fed. Cir. 1991).

**B. The Pending Rejection Should Be Withdrawn**

In the parent Serial No. 07/260,574 application, the Examiner has rejected Claims 16 and 23 under 35 U.S.C. §102(b) as anticipated by Vaeck or Fischhoff, and thus rejects all pending claims related to claims 16 and 23 added by amendment herein. Vaeck was published in July 1987 and is not prior art under 35

U.S.C. §102(b) to the first or second application, and therefore is not prior art to the third application which claims priority to the first two.

Vaeck discloses the use of Agrobacterium-mediated T-DNA transfer of different chimeric Bt insecticidal protein genes of strain berliner 1715 into tobacco plants. Determinations were made of the toxicity to M. sexta larvae which were fed leaves of the tobacco plants expressing the protein.

Fischhoff was published in August 1987 and also fails as prior art under 35 U.S.C. §102(b) for the same reasons as Vaeck. Fischhoff discloses the use in transgenic tomato plants of full length and truncated forms of a B.t. kurstaki HD-1 insect control protein gene and reports measurements of the insecticidal toxicity of leaves of such plants for M. sexta larvae.

The Examiner has used both references as support for her assertion of anticipation based on published accounts of the toxicity of plants expressing truncated insecticidal protein genes. Attorneys for Applicants respectfully disagree with the Examiner's rejections under 35 U.S.C. §102 and submit, for reasons provided below, that the pioneering invention of Applicants is not in any way anticipated by the cited references.

Applicants bring to the Examiner's attention the teachings of the first application which describes and exemplifies a truncated gene encoding a protein that is about 90 kD at pages 37-39 of the first application. The expressed protein is proteolytically cleaved to result in an insecticidal protein fragment of about 68 kD. Moreover, the CIP applications amplify and exemplify the teachings of the specification of the first application and serve to illustrate additional truncated genes producing protein fragments that are insecticidal.

Applicants are, therefore, entitled to the filing date of the first application which predates these cited references by

several years and specifically exemplifies truncated insecticidal proteins. Toxicity of a truncated insecticidal protein gene expressed in plant cells is, thus, disclosed and exemplified in the first application. Moreover, additional regenerated plants produced according to the teachings of the first application are exemplified in the second application. Because both applications predate the cited references, this rejection and argument against the patentability of Claims 16 and 23 fails.

Applicants respectfully submit that the rejection based on the Vaeck or Fischhoff references of Claims 16 and 23, and all newly added claims that this rejection would apply to, under 35 U.S.C. §102(b) should be withdrawn.

In the parent Serial No. 07/260,574 application, the Examiner has rejected Claims 15, 16, 18 and 22-25 and thus all related pending claims under 35 U.S.C. §102(a) as anticipated by DeGreve. The Examiner is mistaken about the publication date of the DeGreve patent, probably due to the European convention of reversing the numbers for month and day as compared to U.S. convention, i.e. in Europe a numerical date is ordered day-month-year versus the U.S. order of month-day-year.

DeGreve was published September 3, 1986 and therefore fails as prior art under 35 U.S.C. §102 for either the first or second priority applications which do describe and exemplify expression of both truncated and full-length insecticidal proteins in plant cells and plants. Applicants have already discussed the description of a truncated insecticidal gene in the first application in the preceding paragraphs of this section. That argument will not be repeated here but additionally rebuts the Examiner's assertions as to truncated embodiments of the invention.

Applicants therefore respectfully request the withdrawal of the rejections based on the Degreve reference of

Claims 15, 16, 18, 22-25, and all the newly added claims that the rejection would apply to under 35 U.S.C. §102(a).

IV. THE INVENTION IS NOT OBVIOUS UNDER 35 U.S.C. §103

A. The Relevant Legal Standards  
Under 35 U.S.C. §103

As articulated by the United States Supreme Court in *Graham v. John Deere Co.*, 383 U.S. 1, 17 (1966), determination of the question of obviousness requires consideration of the scope of the prior art, the level of skill in the pertinent art, and the differences between the prior art and the claimed invention. Both the suggestion to combine the teachings of the references and a reasonable likelihood of success must be found in the prior art and not in the disclosure of the Applicants. *In re Dow Chemical Co.*, 5 U.S.P.Q.2d 529, 1531 (Fed. Cir. 1988).

B. The Pending Rejections Under  
35 U.S.C. §103 Should Be Withdrawn

In the parent Serial No. 07/260,574 application, the Examiner has rejected Claims 16 and 23 and thus all related newly added claims, under 35 U.S.C. §103 as unpatentable over Vaeck or Fischhoff when taken with Wong, Held or Klier. Attorneys for Applicants respectfully disagree with the Examiner's rejections under 35 U.S.C. §103 and submit, for reasons provided below, that the pioneering invention of Applicants is not in any way rendered obvious by the cited references.

The primary references of Vaeck or Fischhoff were published in 1987, well after the filing dates of the first and second applications. The secondary references can not be used alone because they fail to predict, disclose or suggest the use of insecticidal gene constructs in plant cells. Absent the success of Applicants' invention, there is no suggestion to combine these references nor any indication that the references

could be successfully combined. A rejection under 35 U.S.C. §103 cannot be based on hindsight using the Applicants' own success as the reason for combining the references. Therefore, the Examiner's rejection is erroneous as a matter of law because the Examiner has misapplied the test for obviousness under 35 U.S.C. §103.

Applicants have already discussed in this amendment the filing date to which Applicant is entitled. Applicants have also already discussed in this amendment the Examiner's mistaken belief that truncated constructs were described only in the third application. Because truncated constructs are described in the first application and because Applicants are entitled to the filing date of the first application, neither of the primary references of Vaeck or Fischhoff are prior art to the first or second priority applications.

For the reasons provided above, Applicants respectfully request that this rejection under 35 U.S.C. §103 of Claims 16 and 23, and to all related newly added claims, based primarily on Vaeck or Fischhoff in view of the Wong, Held or Klier secondary references be withdrawn.

In the parent Serial No. 07/260,574 application, the Examiner has rejected Claims 15-25 and thus, all pending claims, under 35 U.S.C. §103 as unpatentable over the primary DeGreve reference taken with Wong, Held, or Klier. As noted above, the Examiner is incorrect about the DeGreve publication date, which is after the first or second priority date of this application. Moreover, the filing date to which the Applicants are entitled is discussed above. This rejection is, therefore, erroneous on its face since the DeGreve reference cannot be considered as prior art. The secondary references, either alone or in combination, fail to predict, suggest or disclose the development of plant cells, tissues or plants that express a Bt insecticidal gene in



amounts sufficient to affect the growth or viability of insects. Therefore, Applicants respectfully request that the rejection of Claims 15-25, and all newly added claims to which the rejection would apply, under 35 U.S.C. §103 based on the primary DeGreve reference in view of the secondary Wong, Held or Klier references be withdrawn.

In the parent Serial No. 07/260,574 application, the Examiner has rejected Claims 15-21 and 23-25, and thus all related pending claims, under 35 U.S.C. §103 as being unpatentable over Bevan, Fraley, Herrera-Estrella or Barton taken with Wong, Held, or Klier in view of Brinster.

The Brinster reference refers to mammalian constructs, eukaryotic mammalian vectors, and expression in mammalian cells and is irrelevant to plants. Bevan, published in July 1983, reports the construction of a chimeric gene encoding antibiotic resistance and its transformation into tobacco plant cells with resulting antibiotic resistance expression in the tobacco cells. Fraley is an August 1983 publication demonstrating the expression of a different antibiotic resistance gene after transformation into petunia, sunflower, carrot and tobacco cells. Herrera is a May 1983 reference disclosing the expression of a different foreign antibiotic resistance gene in tobacco cells. The Barton reference was published after September 1987 and can not be used as a prior art reference since it postdates the filing of the first and second priority applications. In sum, none of these references has anything to do with conferring insect resistance on a plant cell. Moreover, none of these references disclose antibiotic-resistant, much less insect-resistant, whole plants or specific plant tissues. Thus, based on these cited references, the Examiner has produced an improper combination of references that fails to suggest, predict or describe the claimed invention

and also fails to render the claimed invention obvious under the patent law principles related to 35 U.S.C. §103.

V. MISCELLANEOUS MATTERS

One minor point unrelated to the rejections that Applicants bring to the Examiner's attention is the correction of the filing receipt for the pending application, Serial No. 07/713,624, which has several errors in dates and the characterization of the latest application as a CIP rather than its proper designation as an FWC continuation application. The proper dates are provided in the introductory paragraph and in footnote 1 of this amendment.

CONCLUSION

The Applicants request entry of the foregoing amendments and remarks, the declaration of Dr. Guy A. Cardineau with its attached exhibits, and Exhibit references A-C with the corresponding attached PTO Form 1449 into the file of the above-captioned application. In light of the above amendment and remarks, the declaration of Dr. Guy A. Cardineau submitted herewith, previous arguments and the declaratory evidence of Dr. Adang submitted previously, Attorneys for Applicants submit that the objections to the specification and the rejections under 35 U.S.C. §§112, 102, 103 have been obviated. Withdrawal of the rejections and reconsideration of all of the pending claims is respectfully requested.

Attorneys for Applicants further submit that the claims as amended and as added herein are in form for issuance and an early allowance is earnestly requested. Attorneys for Applicants will be happy to speak with the Examiner regarding this invention and the pending claims, in the interest of rapidly prosecuting and obtaining allowance of all of the pending claims. The

Applicants would also be very appreciative if the Examiner would indicate the reasons allowance has been granted according to MPEP §1302.03. If any discussion is desired or clarification of any issue can be provided by the Attorneys for Applicants, however minor, the Examiner is respectfully requested to call Dr. Jennifer Gordon at (212) 790-9090.

Respectfully submitted,

Date: April 13, 1992

S. Leslie Misrock 18,872  
S. LESLIE MISROCK (Reg. No.)

By: Jennifer Gordon 30,753  
JENNIFER GORDON (Reg. No.)

FENNIE & EDMONDS  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**